Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ANTA PHAR       

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 2,10 M
EBIT 2016 -59,5 M
Net income 2016 -64,4 M
Debt 2016 -
Yield 2016 -
Sales 2017 0,35 M
EBIT 2017 -68,1 M
Net income 2017 -62,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 13,0x
Capi. / Sales2017 79,0x
Capitalization 27,3 M
More Financials
Company
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on developing and commercializing products to treat treat serious and life-threatening diseases, including lupus, lupus with glomerulonephritis, IgA nephropathy, and exocrine pancreatic insufficiency due to cystic... 
More about the company
Surperformance© ratings of ANTA PHAR
Trading Rating : Investor Rating :
More Ratings
Latest news on ANTA PHAR
02/17 ROBBINS ARROYO LLP : Anthera Pharmaceuticals, Inc. (ANTH) Misled Shareholders Ac..
02/17 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Notice of Delisting or..
02/16 ANTHERA PHARMACEUTICALS INC : Notice of Delisting or Failure to Satisfy a Contin..
01/17 Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anthera Pharmac..
01/13 Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violatio..
01/08 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Regulation FD Disclosu..
01/06 ANTHERA PHARMACEUTICALS INC : Regulation FD Disclosure (form 8-K)
2016 WEDNESDAY SECTOR LAGGARDS : Music & Electronics Stores, Biotechnology Stocks
2016 ANTHERA PHARMACEUTICALS : ANTH) Falls on Missing Endpoint
2016 ANTHERA PHARMACEUTICALS, INC. (NASDA : ANTH) Files An 8-K Other Events
More news
Sector news : Bio Therapeutic Drugs
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Bio Therapeutic Drugs
Advertisement
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 5
Average target price 2,85 $
Spread / Average Target 338%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John Craig Thompson President, Chief Executive Officer & Director
Paul F. Truex Executive Chairman
May Liu CAO, Senior VP-Finance & Administration
Charles V. Olson Chief Technology Officer
William R. Shanahan Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ANTA PHAR27
AMGEN, INC.18.42%127 509
CELGENE CORPORATION3.19%92 920
GILEAD SCIENCES, INC.-3.24%91 287
REGENERON PHARMACEUTIC..1.23%39 421
ACTELION LTD22.45%28 891
More Results